128 related articles for article (PubMed ID: 36503175)
21. Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm.
Wang YH; Yang QC; Lin Y; Xue L; Chen MH; Chen J
Medicine (Baltimore); 2014 Dec; 93(27):e247. PubMed ID: 25501094
[TBL] [Abstract][Full Text] [Related]
22. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients.
Chou WC; Hung YS; Hsu JT; Chen JS; Lu CH; Hwang TL; Rau KM; Yeh KY; Chen TC; Sun CF
Neuroendocrinology; 2012; 95(4):344-50. PubMed ID: 22343505
[TBL] [Abstract][Full Text] [Related]
23. Neuroendocrine tumors (NETs) - experience of a single Center.
Şincu MC; Cocuz IG; Tinca AC; Niculescu R; Sabău AH; Chiorean DM; Morariu SH; Cotoi OS
Rom J Morphol Embryol; 2021; 62(2):457-463. PubMed ID: 35024733
[TBL] [Abstract][Full Text] [Related]
24. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
25. Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms.
Rubino M; Scoazec JY; Pisa E; Faron M; Spaggiari L; Hadoux J; Spada F; Planchard D; Cella CA; Leboulleux S; De Marinis F; Ducreux M; Lamartina L; Baudin E; Fazio N
Lung Cancer; 2020 Oct; 148():149-158. PubMed ID: 32916569
[TBL] [Abstract][Full Text] [Related]
26. Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors.
Cheng Y; Sun Z; Bai C; Yan X; Qin R; Meng C; Ying H
Tumour Biol; 2016 Mar; 37(3):2863-9. PubMed ID: 26408184
[TBL] [Abstract][Full Text] [Related]
27. [On detection of chromogranin A, synaptophysin, neuronspecific enolase and progastrin-releasing peptide in small cell lung cancer].
Lu QQ; Li J; Li YH; Liu H; Xie XB
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jul; 56(7):1017-1022. PubMed ID: 35899358
[TBL] [Abstract][Full Text] [Related]
28. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities.
Swarts DR; Ramaekers FC; Speel EJ
Biochim Biophys Acta; 2012 Dec; 1826(2):255-71. PubMed ID: 22579738
[TBL] [Abstract][Full Text] [Related]
29. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours.
Kasprzak A; Zabel M; Biczysko W
Pol J Pathol; 2007; 58(1):23-33. PubMed ID: 17585539
[TBL] [Abstract][Full Text] [Related]
30. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia with a central and peripheral carcinoid and multiple tumorlets: a case report emphasizing the role of neuropeptide hormones and human gonadotropin-alpha.
Oba H; Nishida K; Takeuchi S; Akiyama H; Muramatsu K; Kurosumi M; Kameya T
Endocr Pathol; 2013 Dec; 24(4):220-8. PubMed ID: 24006219
[TBL] [Abstract][Full Text] [Related]
31. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors.
Jiang SX; Kameya T; Asamura H; Umezawa A; Sato Y; Shinada J; Kawakubo Y; Igarashi T; Nagai K; Okayasu I
Mod Pathol; 2004 Feb; 17(2):222-9. PubMed ID: 14657947
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
[TBL] [Abstract][Full Text] [Related]
33. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
34. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer.
Petrović M; Bukumirić Z; Zdravković V; Mitrović S; Atkinson HD; Jurišić V
Med Oncol; 2014 Feb; 31(2):823. PubMed ID: 24375395
[TBL] [Abstract][Full Text] [Related]
35. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
36. Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
[TBL] [Abstract][Full Text] [Related]
37. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
Lamy PJ; Grenier J; Kramar A; Pujol JL
Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
[TBL] [Abstract][Full Text] [Related]
38. NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease.
Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk A; Filosso PL; Wójcik-Giertuga M; Rydel M; Zielińska-Leś I; Walter A; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Jamidar P; Ziora D; Czyżewski D; Kos-Kudła B; Ćwikła J
Neuroendocrinology; 2019; 108(3):219-231. PubMed ID: 30654372
[TBL] [Abstract][Full Text] [Related]
39. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.
Cui T; Hurtig M; Elgue G; Li SC; Veronesi G; Essaghir A; Demoulin JB; Pelosi G; Alimohammadi M; Öberg K; Giandomenico V
PLoS One; 2010 Dec; 5(12):e16010. PubMed ID: 21209860
[TBL] [Abstract][Full Text] [Related]
40. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
